Analysis and recommendations on whether Trelagliptin is suitable for patients with type 1 diabetes

Trelagliptin (Trelagliptin) is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, mainly used for< For patients with type 2 diabetes, by prolonging the action time of insulin secretagogue (GLP-1) in the body, it increases postprandial insulin secretion while inhibiting the release of glucagon, thereby effectively improving blood sugar control. Its mechanism of action depends on the function of the patient's own pancreatic islet beta cells, so it has limited efficacy in patients with type 1 diabetes who have lost pancreatic islet beta cell function.

For patients with type 1 diabetes, due to severe impairment or almost complete loss of their own pancreatic β-cell function, it is difficult to significantly increase insulin levels and effectively control blood sugar using trotagliptin alone. Therefore, troagliptin is currently not the first-choice drug in type 1 diabetes. The standard treatment is still based on insulin replacement therapy, including basic -prandial insulin injection or insulin pump therapy to meet the patient's daily insulin requirements.

However, in certain circumstances, trotagliptin may be used as an adjunct. For example, for some type 1 diabetic patients with remaining pancreatic islet beta cell function, the use of trolagliptin in combination with insulin may help improve postprandial blood sugar fluctuations, reduce insulin dosage, and reduce the risk of hypoglycemia. However, this combined treatment needs to be carried out under the guidance of a professional endocrinologist, and blood sugar changes and insulin dose adjustments must be strictly monitored.

In general, trotagliptin is not suitable as a single treatment for type 1 diabetes, but it can be used as an adjunctive drug in selected patients to optimize blood sugar management. In clinical practice, joint use should be carefully evaluated based on the patient's pancreatic beta cell function, blood sugar level, and risk of hypoglycemia, and an individualized treatment plan should be formulated under the guidance of a professional doctor to ensure efficacy and medication safety.

Reference link:https://www.drugs.com